Tumor marker requests in a general teaching Turkish hospital

Indian Journal of Clinical Biochemistry

Volumn 22, Issue 1, 2007, Pages 52-56

  Yilmaz, Gülsen ^a   Yilmaz, Fatma Meriç ^a   Senes, Mehmet ^a   Yucel, Dogan ^a  

^a ANKARA NUMUNE HOSPITAL   (Turkey)

Author keywords

Cancer; Evidence based laboratory medicine; Laboratory management; Tumor markers

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CARBOHYDRATE ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; DATA BASE; EVIDENCE BASED MEDICINE; FEMALE; HOSPITAL; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; MEDICAL STAFF; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; TRAINING;

EID: 33947155227     PISSN: 09701915     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02912881     Document Type: Article

References (15)

1. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865-78.
2. Ruoslahti E, Salaspuro M, Pihko H, Anderson L, Seppala M. Serum α-fetoprotein: diagnostic significance in liver disease. Br Med J 1974; 8: 527-9.
3. Fletcher RH. Carcinoembrionic antigen. Ann Intern Med 1986; 104: 66-78.
4. Thomas P, Zamcheck N. Role of liver in clearance and excretion of circulating carcinoembriogenic antigen (CEA). Dig Dis Sci 1983; 28: 216-24.
5. Jacops IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer; a pilot randomised controlled trial. Lancet 1999; 353: 1207-10.
6. Gallup DG, Talledo E. Management of the adnexial mass in the 1990s. South Med J 1997; 90: 972-81.
7. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990; 85: 350-5.
8. Mazumdar M, Bajorin D, Bacik J, Higgins G, Motzer RJ, Bost GI. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 2001; 19: 2534-41.
9. Carter HB, Pearson JD, Metter EJ, Brant L, Chan DW, Andrea R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 257: 2215-20.
10. Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem 2002; 48: 1151-9.
11. European Society for Medical Oncology. ESMO minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of colon cancer. Ann Oncol 2001; 12: 1053-4.
12. McDonnell M. An audit of tumor marker requests in Northern Ireland. Ann Clin Biochem 2004; 41: 378-84.
13. Duffy MJ. CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 1998; 35: 364-70
14. Klaptor R, Aranson AC, Duffy MJ, Hansson LO, Khalifa R, Lamerz R, et al. Tumor markers in gastrointestinal cancers: EGTM recommendations. Anticancer Res 1999; 19: 2807-10.
15. Rustin GJ. The clinical value of tumor markers in the management of ovarian cancer. Ann Clin Biochem 1996; 33: 284-9.